Human Enhancement: Therapy, Upgrade and a New Inequality

Enhancement is not one single thing

Philosophical literature under the label human enhancement groups together very different practices. Glasses improve vision, training improves physical performance, education develops cognitive abilities, and medicine can return a person from illness toward ordinary functioning. The Stanford Encyclopedia of Philosophy therefore notes that the ethical problem is not simply that a capacity is increased, but the purpose, method, risk, fairness, and social context of the intervention.

This article focuses on the narrower and more controversial category: biological, genetic, pharmacological, or neurotechnological redesign of healthy people, especially beyond treatment. This is where the question changes from whether technology serves a person to whether the person is being adapted to a performance standard set by markets, militaries, employers, competitive institutions, or an ideology of progress.

In practice, the line between therapy and enhancement is not always sharp. The same hormone, neurostimulation method, or genetic technique might treat a disorder in one setting and attempt to raise healthy function beyond the ordinary range in another. But a grey boundary is not a meaningless boundary. Purpose and the person’s starting condition materially change the moral burden of an intervention.

For severe disease, a risky intervention may be justified because the person already bears a heavy burden. A healthy person does not begin from the same place. The threshold for invasiveness, long-term uncertainty, and irreversibility should therefore be much higher. A risk that is reasonable when treating paralysis is not automatically reasonable for a few percentage points of productivity or competitive advantage.

THY-REALITY does not use the simple formula natural = good, artificial = bad. Natural toxins can kill, while an artificially manufactured antibiotic can save a life. The criticism of enhancement therefore rests not on fear of everything technological but on necessity, proportionality, and sovereignty.

The value boundary is different: the healthy human body and mind should not be treated as an obsolete platform that must be technically corrected to fit a future system. When technology removes disease or replaces lost function, it serves the person. When a healthy person is expected to alter biology mainly because otherwise they will not be competitive enough, the direction of service has reversed.

Medical success is not a licence to redesign healthy people

The strongest reason for caution is precisely the success of modern medicine. Gene therapies, neuroprostheses, and advanced medical devices can help people in ways that recently seemed impossible. But therapeutic success does not establish the ethical acceptability of enhancement. Treating disease and manufacturing new traits are different goals.

When the same technical vocabulary moves from the clinic into a commercial catalogue of traits, the questions change: who defines a 'better' human, who pays, who lacks access, who carries long-term risk, and what happens to people who do not want to participate?

Casgevy is a useful contrast because it is an approved somatic genome-editing treatment. By July 2026, the FDA had approved it for certain patients aged two and older with sickle-cell disease and transfusion-dependent beta-thalassemia. Cells are edited to treat serious disease; the intervention is not designed to transmit an alteration to descendants.

That distinction matters. The fact that CRISPR can already treat patients does not establish that the same logic should be used to design healthy children with selected traits. Technical capability is not automatic moral permission. Every new purpose requires a new evidential and ethical accounting.

Somatic editing changes cells in the person being treated; germline or heritable editing can pass changes to future generations. The WHO therefore treats heritable genome editing as carrying substantially greater safety and ethical concerns and continues to state that proceeding prematurely to clinical germline editing would be irresponsible.

A heritable intervention is no longer only a patient deciding about their own body. It can affect people who do not yet exist and cannot consent, as well as later generations. At that threshold, 'my body, my choice' is not sufficient, because the future person’s body is not the property of the present decision-maker.

The He Jiankui case moved the boundary from theory into reality

In 2018, He Jiankui announced the birth of the first children whose embryos had been genome-edited with CRISPR. The experiment drew broad international condemnation over safety, consent procedures, and the lack of compelling medical necessity. It demonstrated something important: heritable redesign of human beings is no longer merely a science-fiction possibility.

That does not mean such editing became safe, ordinary, or socially accepted. The opposite followed: international bodies intensified calls for governance and public deliberation. This article uses the episode to show why ethics must get ahead of deployment rather than chase technology after a boundary has already been crossed.

Preimplantation genetic testing does not alter an embryo’s DNA; it uses genetic information to help choose among existing embryos. For severe monogenic disease, the aim may be to avoid a large and well-defined health risk. Polygenic embryo screening (PGT-P), however, attempts to estimate probabilities for complex conditions and traits influenced by many variants as well as environment.

In its 2026 ethics opinion, ASRM concluded that PGT-P is not currently ready for routine clinical use and should not be used for nonmedical trait selection. That is an important boundary between preventing disease and building a catalogue for ranking future children by presumed genetic 'quality'.

Complex traits such as height, cognitive performance, and risk for many common diseases are not produced by a single gene. Polygenic scores aggregate large numbers of statistical associations, and their predictive value depends on population, environment, data, and modeling choices. A Nature Human Behaviour study showed that the ranking of the same embryos can vary substantially across polygenic-scoring methods.

It would therefore be dangerous to market a polygenic score as an objective ladder of future human value. A gene is not destiny and a score is not prophecy. Even for health applications, uncertainty must be communicated; for nonmedical traits the problem grows because a statistical model can quickly become a cultural judgment about which child is supposedly 'better'.

Future generations cannot sign a consent form

Heritable enhancement creates a special asymmetry: parents or institutions make the intervention while descendants may carry the consequences. The International Commission convened by the U.S. National Academies and the Royal Society therefore concluded that heritable editing should not enter clinical use until precise genomic changes can be made reliably without undesired changes and that broad societal dialogue would be required before any country permits clinical use.

For treatment of a severe inherited disorder, there is at least a clearly defined medical target. Enhancement of a healthy embryo is different: the aim is not to remove disease but to decide in advance which characteristics are preferred. That is power over a person before their existence, and it requires more than a private consumer decision by prospective parents.

Today’s cell and gene therapies already show how difficult it is to provide equitable access to extremely expensive biomedical technologies. The WHO has noted that advanced cell and gene therapies often cost more than one million U.S. dollars per patient, while recent scholarship documents substantial geographic and financial disparities in access.

These are treatments for sick people, not enhancements. That is precisely why they matter as a warning. If health systems already struggle to distribute technologies that treat severe disease, there is little basis for assuming that expensive enhancements for healthy people would spontaneously become equally available to everyone.

Ordinary wealth already buys differences in housing, schooling, time, and social networks. Biological or cognitive enhancement could add another layer: wealthier people might purchase not only a better environment but interventions intended to increase the physical or cognitive performance of themselves or their children. For now, this is primarily an ethical forecast, not evidence that a new genetic caste already exists.

The scenario is nevertheless serious enough to appear in UNESCO work, bioethics, and contemporary reviews of enhancement. If advantage becomes bodily or heritable and then converts into better education, employment, and wealth, social inequality could begin reproducing itself partly through the technology of the body.

Even 'equal access for everyone' does not solve coercion

A common reply is that enhancement is acceptable if everyone can access it. That addresses one part of distributive justice but not coercion. If every competitor can enhance, an option can rapidly become the new normal: a person who refuses is no longer free in the same sense if refusal systematically costs them opportunities.

Such coercion requires neither law nor police. Competition can produce it. If an employer formally does not require cognitive stimulation but enhanced workers advance; if a military rewards greater endurance; if students are assessed in an environment where some use biological performance boosters — 'voluntary' can become little more than a word on a form.

Enhancement is often a positional good: its value lies partly in advantage over others, not only in absolute ability. If one group acquires technologically increased performance, another group may feel pressure to follow even when it does not want the intervention. A competitive spiral can result: everyone spends more and accepts more risk while relative positions change little.

This is one of the strongest reasons to defend a right not to enhance. A free society should not measure human worth by the number of technical interventions a person is willing to accept. The unmodified human must not become a new category of 'insufficiently optimized' person.

Modern sport is a useful example because it openly distinguishes training from some forms of artificial performance advantage. The World Anti-Doping Agency’s 2026 Prohibited List includes specified forms of gene and cell doping. The reason is not that every technology is evil, but that competition needs boundaries around safety and fairness.

Society outside sport is more complex and has no single rulebook. Yet the logic remains: greater performance alone is not enough to make an intervention ethically good. We must ask what kind of world emerges if a person has to alter their biology simply to remain on the starting line.

Neuroenhancement of healthy people: promises currently exceed evidence

For neurostimulation and BCI-based enhancement in healthy people, there is a large gap between research possibilities and promotional narratives. A 2024 systematic scoping review found insufficient high-quality evidence on efficacy and safety for enhancing brain function in healthy people, while also identifying invasive risks and potential socioeconomic consequences.

That is an important correction to 'upgrade now' ideology. In a healthy person, a lasting intervention cannot be justified by hypothetical future benefit alone. First there must be evidence that a benefit exists, then that it is large enough, then that it is safe — only after that comes the question of whether the goal itself is worth pursuing.

Pharmacological cognitive enhancers are often presented as a softer version of the same project. A review of so-called nootropics in healthy people found that effects of many substances remain uncertain, any reported benefits may be temporary, and risks can include cardiovascular, neurological, and psychiatric complications depending on the drug.

This article therefore neither romanticizes nor demonizes a particular molecule. The larger issue is social: if a pharmaceutical performance booster becomes an expected norm for study or work, treatment and individual choice can slide into a system of normalized chemical competition.

DARPA’s N3 programme publicly described a goal of developing high-performance bidirectional brain–machine interfaces for able-bodied service members. The UK paper Human Augmentation – The Dawn of a New Paradigm likewise examined genetic, neurotechnological, and other forms of enhancement for defence, while explicitly stating that it was a think-piece rather than official government or Ministry of Defence policy.

That is enough for legitimate criticism without speculation. Institutional interest exists and is documented. It does not establish a single hidden programme to redesign the general population. This article therefore attacks the real issue: military settings are highly hierarchical, so the line between voluntary research and career pressure around interventions in healthy bodies deserves unusually strong protection.

Disability is not an argument for a project of 'fixing humanity'

Criticism of enhancement must not demean people who use prostheses, implants, or other assistive technologies. For a person without a hand, a bionic prosthesis may increase independence; for a person with paralysis, a BCI may provide communication. Restorative technology is not evidence that the healthy body is defective.

Nor should complex human diversity be reduced to a 'better–worse genome' ladder. UNESCO emphasizes dignity and rights regardless of genetic characteristics and warns against reducing individuals to their genetic profile. This article therefore combines two protections: help people when they need it, and resist turning technology into a new standard of human worth.

A person can be free on paper to refuse an enhancement, yet the right becomes hollow if refusal costs employment, insurance, education, or normal social participation. A meaningful right not to enhance requires protection against discrimination whenever remaining unenhanced poses no concrete and demonstrable risk to others.

This principle matters especially for healthy children, workers, military personnel, and others with limited bargaining power. For them, 'did you agree?' must be supplemented by 'what would have happened if you said no?'. Consent without a realistic ability to refuse is weak consent.

Borgification: When the Human Becomes Part of the Network examined in detail how bodily technology can depend on software, manufacturers, and networks. Enhancement sharpens the issue: if a new capacity only works with a licence, update, cloud service, or one vendor’s maintenance, a person has not merely purchased an ability — they have entered a long-term dependency relationship.

For a medical device, such a compromise may sometimes be justified by health needs. For elective enhancement of a healthy person, it is harder to explain why progress in human freedom should require greater technical and contractual dependence. An upgrade can improve performance while simultaneously reducing sovereignty if it weakens the ability to exit.

Dignity is not a measure of IQ, muscle power, or market usefulness

UNESCO’s declaration on the human genome begins from the principle that dignity and rights belong to people regardless of genetic characteristics and that individuals should not be reduced to them. This becomes especially important in an enhancement society: when technology enables ranking people by selected or implanted capacities, markets can quickly turn an 'option' into a new scale of human value.

THY-REALITY therefore rejects an anthropology in which a person is worth as much as they are optimized. Human dignity must come before technology, or technology stops serving people and becomes the metric by which people themselves are judged.

There are important historical and moral links among selection, heredity, and social ideas of 'better' humans, but this article does not equate modern gene therapy or every reproductive technology with historical eugenic programmes. Those programmes involved specific ideologies, state policies, coercion, and in many cases grave violations of human rights.

The comparison deserves precision and is therefore owned by Eugenics: How “Improving Humanity” Became a Political Project. For this article, one warning is sufficient: whenever future children are ranked by 'desirable' and 'less desirable' traits, we must ask who defines the criterion and what power that criterion creates over those who do not meet it.

Science has not demonstrated that human potential is literally unlimited, and THY-REALITY does not present that as an empirical fact. But neither is there good reason to treat today’s average cognitive, physical, or creative performance as the final boundary of the human being. Learning, training, health, community, discipline, creativity, and exploration of consciousness can substantially change what a person can actually do.

This article’s resistant question is therefore simple: why redesign the human before developing the human? Technology can remain an extraordinarily powerful external tool. It is not self-evident that it must become an internal substitute for capacities we do not yet fully understand.

A human-sovereignty test: twelve questions before any upgrade

Before altering a healthy person, ask: Are we treating disease or creating competitive advantage? How strong is the evidence of benefit? What are the short- and long-term risks? Is the intervention reversible? Does it affect descendants? Who owns the data and technology? Is function dependent on a vendor? Who can afford it? What happens to those who refuse? Can a child or employee truly say no? Is there a less invasive alternative? And ten years later, does the intervention increase or reduce the person’s independence?

These questions are not a ban on science. They are a demand that science and markets do not receive automatic moral permission merely because something can be built. For a healthy person, the burden of proof belongs to those who want to modify the human being — not to the person who wishes to remain unenhanced.

The largest danger of enhancement is not a single device or gene. It is a change in the social baseline: the moment the natural human becomes the lower-tier default model and the enhanced human becomes the new norm for productivity, safety, or prestige. Such a world could increase capability while reducing freedom.

This article therefore ends with a clear order of priorities. Treat disease. Restore what has been lost. Develop existing human capacities. Use technology as a tool. And be deeply cautious of the idea that a healthy person must redesign body, brain, or descendants merely to be good enough for a system we ourselves created.